So, Is leptin good or bad in chronic kidney disease?

Obesity

Volumn 15, Issue 6, 2007, Pages 1343-1344

  Kalantar Zadeh, Kamyar ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEPTIN;

ANIMAL; BLOOD; CHRONIC KIDNEY FAILURE; HUMAN; MORTALITY; MOUSE; NOTE; PHYSIOLOGY; RISK FACTOR;

ANIMALS; HUMANS; KIDNEY FAILURE, CHRONIC; LEPTIN; MICE; RISK FACTORS;

EID: 34547225123     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.161     Document Type: Note

References (28)

1. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292-5.
2. Mak RH, Cheung W, Cone RD, Marks DL. Leptin and inflammation-associated cachexia in chronic kidney disease, Kidney Int. 2006;69:794-7.
3. Nordfors L, Lonnqvist F, Heimburger O, Danielsson A, Schalling M, Stenvinkel P. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int. 1998;54:1267-75.
4. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. Appetite and inflammation, nutrition, anemia and clinical outcome in hemodialysis patients. Am J Clin Nutr. 2004;80:299-307.
5. Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest. 2005;115:1659-65.
6. Stenvinkel P, Lindholm B, Lonnqvist F, Katzarski K, Heimburger O. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol. 2000;11:1303-9.
7. Odamaki M, Furuya R, Yoneyama T, et al. Association of the serum leptin concentration with weight loss in chronic hemodialysis patients. Am J Kidney Dis. 1999;33:361-8.
8. Heimburger O, Lonnqvist F, Danielsson A, Nordenstrom J, Stenvinkel P. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol. 1997;8:1423-30.
9. Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol. 1998;9:1080-4.
10. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med. 1996;335:1897-905.
11. Zheng F, Qiu X, Yin S, Li Y. Changes in serum leptin levels in chronic renal failure patients with metabolic acidosis. J Ren Nutr. 2001;11:207-11.
12. Kalantar-Zadeh K, Mehrotra R, Fouque D, Kopple JD. Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. Semin Dial. 2004;17:445-65.
13. Don BR, Resales LM, Levine NW, Mltch W, Kaysen GA. Leptin is a negative acute phase protein in chronic hemodialysis patients. Kidney Int. 2001;59:1114-20.
14. Pecoits-Filho R, Lindholm B, Stenvinkel P. End-stage renal disease: a state of chronic inflammation and hyperleptinemia. Eur J Clin Invest. 2003;33:527-8.
15. Iglesias P, Diez JJ, Fernandez-Reyes MJ, et al. Effects of short-term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients. Nephrol Dial Transplant. 2002;17:260-4.
16. Fouque D, Juillard L, Lasne Y, Tabakian A, Laville M, Joly MO. Acute leptin regulation in end-stage renal failure: the role of growth hormone and IGF-1. Kidney Int. 1998;54:932-7.
17. Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr. 2005;15:345-55.
18. Aguilera A, Bajo MA, Rebollo F, et al. Leptin as a marker of nutrition and cardiovascular risk in peritoneal dialysis patients. Adv Perit Dial. 2002;18:212-7.
19. Nasri H. Serum leptin concentration and left ventricular hypertrophy and function in maintenance hemodialysis patients. Minerva Urol Nefrol. 2006;58:189-93.
20. Kalantar-Zadeh K, Abbott KC, Kronenberg F, Anker SD, Horwich TB, Fonarow GC. Epidemiology of dialysis patients and heart failure patients. Semin Nephrol. 2006;26:118-33.
21. Scholze A, Rattensperger D, Zidek W, Tepel M. Low serum leptin concentration predicts mortality in patients with chronic kidney disease stage 5 on hemodialysis therapy. Obesity (Silver Spring). 2007;15:1617-22.
22. Kalantar-Zadeh K, Kopple JD. Obesity paradox in patients on maintenance dialysis. Contrib Nephrol. 2006;151:57-69.
23. Kalantar-Zadeh K, Abbott KG, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005;81:543-54.
24. Kilpatrick RD, Derose SF, Kovesdy CP, McAllister CJ, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and the impact of race J Am Soc Nephrol. 2007;18:293-303.
25. Suliman ME, Barany P, Kalantar-Zadeh K, Lindholm B, Stenvinkel P. Homocysteine in uraemia - a puzzling and conflicting story. Nephrol Dial Transplant. 2005;20:16-21.
26. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793-808.
27. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, Wu DY. Reverse epidemiology: a spurious hypothesis or a hardcore reality? Blood Purif. 2005;23:57-63.
28. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346:570-8.